BiotechTube

Monovalent Influenza Vaccine

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Influenza

Conditions

Influenza, Healthy

Trial Timeline

May 2, 2016 → Nov 30, 2016

NCT ID
NCT02743117

About Monovalent Influenza Vaccine

Monovalent Influenza Vaccine is a approved stage product being developed by AstraZeneca for Influenza. The current trial status is completed. This product is registered under clinical trial identifier NCT02743117. Target conditions include Influenza, Healthy.

What happened to similar drugs?

20 of 20 similar drugs in Influenza were approved

Approved (20) Terminated (2) Active (0)
✅Monovalent Influenza VaccineAstraZenecaApproved
✅Trivalent Influenza VaccineAstraZenecaApproved
✅Trivalent Influenza VaccineAstraZenecaApproved
✅FluMist trivalent (2015-2016) + FluMist Quadrivalent (2015-2016) + FluMist Quadrivalent (2017-2018)AstraZenecaApproved
✅Trivalent Influenza Virus VaccineAstraZenecaApproved
✅Vaxelis + PedvaxHIBMerckApproved
✅Fluvirin(TIVf) + Agriflu (TIV)NovartisApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT03158038ApprovedCompleted
NCT02743117ApprovedCompleted

Competing Products

20 competing products in Influenza

See all competitors
ProductCompanyStageHype Score
mRNA-1010ModernaPhase 1
0
mRNA-1273ModernaPhase 1
0
mRNA-1010ModernaPhase 2
0
mRNA-1083 Composition 1 Dose A Lot AModernaPhase 2
0
mRNA-1010ModernaPhase 3
0
mRNA-1011.1ModernaPhase 2
0
mRNA-1083.1ModernaPhase 2
0
mRNA-1010ModernaPhase 3
0
mRNA-1083ModernaPhase 3
0
mRNA-1073ModernaPhase 2
0
VAL-506440ModernaPhase 1
0
mRNA-1083ModernaPhase 3
0
mRNA-1083ModernaPhase 2
0
mRNA-1010ModernaPhase 3
0
VAL-339851ModernaPhase 1
0
mRNA-1018-H5ModernaPhase 3
0
mRNA-1653ModernaPhase 1
0
mRNA-1030ModernaPhase 2
0
mRNA-1018 for H5N8ModernaPhase 2
0
mRNA-1653ModernaPhase 1
0